A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia
Phase 2
Completed
NCT02255435
| Condition | Friedreich Ataxia |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Biogen |
|---|
| Status | Completed |
|---|
| Enrollment | 172 participants |
|---|
| Interventions | Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg, Omaveloxolone Capsules, 10 mg, Omaveloxolone Capsules, 20 mg, Omaveloxolone Capsules, 40 mg |
|---|
| Start date | Jan 31, 2015 |
|---|
| Completion date | Oct 31, 2019 |
|---|
| Results posted | Nov 29, 2022 |
|---|
Summary
In this study, researchers are learning more about RTA 408, also known as omaveloxolone, BIIB141, or SKYCLARYS®. The main goal of this study is to learn more about the safety of RTA 408 and how it affects physical effort, movement, coordination, and how participants feel in daily life. The main questions researchers want to answer in this study are: * How much physical effort can a participant produce during a cycling test after 12 weeks of treatment? * How do scores on the modified Friedreich's Ataxia Rating Scale (mFARS) change after 48 weeks? Researchers will use the modified Friedreich's Ataxia Rating Scale (mFARS) to measure how FA affects the nervous system. The mFARS looks at movement ability, balance, coordination, speech, and how well the arms and legs work. They will also use a cycling test to measure physical effort, along with questionnaires to learn how participants feel and function in daily life. Safety will also be tested using physical exams, vital sign checks, echocardiograms (ECHO), electrocardiograms (ECG), and blood and urine tests. The study will be done in 2 main parts, followed by an optional Extension period: * In Part 1, participants will be randomly assig
Change From Baseline in Peak Work (in Watts/kg) During Exercise Testing at Week 12 in Part 1
Baseline through 12 weeks after participant receives the first dose in Part 1. · W/kg
| Part 1 Omaveloxolone Capsules 2.5 and 5 mg | 0.14 W/kg |
|---|
| Part 1 Omaveloxolone Capsules 10 mg | 0.07 W/kg |
|---|
| Part 1 Omaveloxolone Capsules 20 mg | -0.09 W/kg |
|---|
| Part 1 Omaveloxolone Capsules 40 mg | 0.06 W/kg |
|---|
| Part 1 Omaveloxolone Capsules 80 mg | 0 W/kg |
|---|
| Part 1 Omaveloxolone Capsules 160 mg | 0.02 W/kg |
|---|
| p-value | 0.1524 |
|---|
| LS Mean difference (Net) | 0.10 (95% CI -0.04–0.23) |
|---|
Change in the Modified Friedreich's Ataxia Rating Scale (mFARS) at Week 48 in Part 2
48 weeks after participant receives the first dose in Part 2 · score on a scale
| Part 2 Placebo Capsules | 0.85 ± 0.640 score on a scale |
|---|
| Part 2 Omaveloxolone Capsules 150 mg | -1.55 ± 0.689 score on a scale |
|---|
| p-value | 0.0141 |
|---|
| LS Mean difference (Net) | -2.40 (95% CI -4.31–-0.50) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.